عنوان

New agents for the treatment of acute lymphoblastic leukemia /

(Number (ISBN

1441984585

(Number (ISBN

1441984593

(Number (ISBN

9781441984586

(Number (ISBN

9781441984593

Erroneous ISBN

9781441984586

Number

b430545

Title Proper

New agents for the treatment of acute lymphoblastic leukemia /

General Material Designation

[Book]

First Statement of Responsibility

Vaskar Saha, Pamela Kearns, editors

Specific Material Designation and Extent of Item

1 online resource (xviii, 338 pages)

Text of Note

Includes bibliographical references and index

Text of Note

New Agents for the Treatment of Acute Lymphoblastic Leukemia; Brief Overview; Acknowledgements; Contents; Contributors; Glossary; Chapter 1: The Need for New Agents; Chapter 2: Identifying Targets for New Therapies in Children with Acute Lymphoblastic Leukemia; Chapter 3: Preclinical Evaluation; Chapter 4: Design of Early-Phase Trials; Chapter 5: Strategies for Trial Design and Analyses; Chapter 6: An Overview on Animal Models of ALL; Chapter 7: Targeting Bcl-2 Family Proteins in Childhood Leukemia; Chapter 8: Targeting Leukemia Stem Cells and Stem Cell Pathways in ALL

Text of Note

Chapter 9: Nucleoside AnaloguesChapter 10: FLT3 Inhibitors as Therapeutic Agents in MLL Rearranged Acute Lymphoblastic Leukemia; Chapter 11: The Role of Tyrosine Kinase Inhibitors in the Treatment of ALL; Chapter 12: Monoclonal Antibodies in Paediatric Acute Lymphoblastic Leukemia; Chapter 13: Therapeutic Utility of Proteasome Inhibitors for Acute Leukemia; Chapter 14: Targeting Epigenetic Pathways in ALL; Chapter 15: Incorporating New Therapies into Frontline Protocols; Index

0

8

Text of Note

New Agents for the Treatment of Acute Lymphoblastic Leukaemia (ALL), examines the strategies for the use of new agents as well as possible targets of therapy in this disease. Though associated with high cure rates, relapsed disease has a poor outcome. Moreover, therapy is unduly prolonged and toxic. For over 4 decades, no new drugs have been available and now we have a surfeit. The challenge is to design trials to evaluate the potential efficacy of non-targeted therapy in a disease with good outcome. An increasing number of pathways, amenable to targeted therapy are also being identified. The heterogeneity of ALL suggests that targeted therapy at the moment will need to be tailored to the patient. How then can such drugs be evaluated within conventional clinical trials? These are the crossroads we have reached in acute lymphoblastic leukaemia and this book discusses and proposes some solutions to these issues

Source for Acquisition/Subscription Address

Springer

Stock Number

978-1-4419-8458-6

Title

New agents for the treatment of acute lymphoblastic leukemia.

Drugs-- Design

Drugs-- Research

Lymphoblastic leukemia-- Chemotherapy

Adolescent

Antineoplastic Agents-- therapeutic use

Child

Clinical Trials as Topic

Precursor Cell Lymphoblastic Leukemia-Lymphoma-- drug therapy

Treatment Outcome

Number

Edition

Class number

Book number

Class number

Class number

Kearns, Pamela

Saha, Vaskar

Date of Transaction

20170726082057.0

Cataloguing Rules (Descriptive Conventions))

pn

Electronic name

[Book]

Y